nach oben

Journal of Neuro-Oncology

Erschienen in:

01.12.2013 | Laboratory Investigation

MicroRNA-650 expression in glioma is associated with prognosis of patients

verfasst von: Boqian Sun, Bo Pu, Dake Chu, Xiaodan Chu, Wei Li, Dun Wei

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs are known as non-coding RNAs that regulate the expression of target mRNA. Accumulating evidence has indicated that microRNA expression in human malignancies can be utilized as a prognostic marker for patients. However, the prognostic value of miR-650 in human glioma has not been investigated yet. In the present investigation, we have recruited 168 cases glioma specimens and 21 normal control brain specimens. Quantitative real-time PCR was carried out to investigate the expression of miR-650. Kaplan–Meier analysis and Cox’s proportional hazards model was used to evaluate the association of miR-650 with prognosis of glioma patients. Results showed that miR-650 expression was increased in glioma compared with normal control specimens (P < 0.001). It was also found that miR-650 expression was related to World Health Organization grade and Karnofsky performance score (KPS) for high expression was more frequently detected in glioma of high grade or low KPS score (P < 0.001). The prognosis of glioma with high miR-650 expression was significantly worse compared with that of glioma with low miR-650 expression. These results proved that miR-650 expression was a significant prognostic indicator in glioma, which may suggest new management of human glioma.

Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(3):255–268PubMedCrossRef

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166 PubMedCrossRef

Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61(3):215–225; discussion 226–219

Tsao-Wei DD, Hu J, Groshen SG, Chamberlain MC (2012) Conditional survival of high-grade glioma in Los Angeles County during the year 1990–2000. J Neuro Oncol 110(1):145–152. doi:10.1007/s11060-012-0949-6 CrossRef

Shirai K, Chakravarti A (2011) Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 11(12):1935–1944. doi:10.1586/era.11.103 PubMedCrossRef

Franceschi E, Stupp R, van den Bent MJ, van Herpen C, Laigle Donadey F, Gorlia T, Hegi M, Lhermitte B, Strauss LC, Allgeier A, Lacombe D, Brandes AA (2012) EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol 14(12):1503–1510. doi:10.1093/neuonc/nos256 PubMedCrossRef

Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60(3):166–193. doi:10.3322/caac.20069 PubMedCrossRef

Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874. doi:10.1038/nrg3074 PubMedCrossRef

Wienholds E, Plasterk RH (2005) MicroRNA function in animal development. FEBS Lett 579(26):5911–5922. doi:10.1016/j.febslet.2005.07.070 PubMedCrossRef

10.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297PubMedCrossRef

11.

Dela Cruz F, Matushansky I (2011) MicroRNAs in chromosomal translocation-associated solid tumors: learning from sarcomas. Discov Med 12(65):307–317PubMed

12.

Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38(6):724–733. doi:10.1053/j.seminoncol.2011.08.006 PubMedCrossRef

13.

Harquail J, Benzina S, Robichaud GA (2012) MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 11(6):269–280. doi:10.3233/CBM-120291 PubMed

14.

Rossi S, Di Narzo AF, Mestdagh P, Jacobs B, Bosman FT, Gustavsson B, Majoie B, Roth A, Vandesompele J, Rigoutsos I, Delorenzi M, Tejpar S (2012) microRNAs in colon cancer: a roadmap for discovery. FEBS Lett 586(19):3000–3007PubMedCrossRef

15.

Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC, Wang ZX (2012) MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytol 56(6):645–654. doi:10.1159/000343473 PubMedCrossRef

16.

Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA (2012) MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer 107(8):1354–1360. doi:10.1038/bjc.2012.383 PubMedCrossRef

17.

Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J, Nazarov PV, Palissot V, Hood LE, Berchem G, Galas DJ (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA 108(16):6573–6578. doi:10.1073/pnas.1019557108 PubMedCrossRef

18.

Guerau-de-Arellano M, Smith KM, Godlewski J, Liu Y, Winger R, Lawler SE, Whitacre CC, Racke MK, Lovett-Racke AE (2011) Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain J Neurol 134(Pt 12):3578–3589. doi:10.1093/brain/awr262 CrossRef

19.

Mouradian MM (2012) MicroRNAs in Parkinson’s disease. Neurobiol Dis 46(2):279–284. doi:10.1016/j.nbd.2011.12.046 PubMedCrossRef

20.

Delay C, Mandemakers W, Hebert SS (2012) MicroRNAs in Alzheimer’s disease. Neurobiol Dis 46(2):285–290. doi:10.1016/j.nbd.2012.01.003 PubMedCrossRef

21.

Tan X, Wang S, Yang B, Zhu L, Yin B, Chao T, Zhao J, Yuan J, Qiang B, Peng X (2012) The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS One 7(11):e49570. doi:10.1371/journal.pone.0049570 PubMedCrossRef

22.

Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW (2013) MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. J Neuro Oncol 111(1):71–81. doi:10.1007/s11060-012-0992-3 CrossRef

23.

Chang C, Shi H, Wang C, Wang J, Geng N, Jiang X, Wang X (2012) Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci Lett 531(2):204–208. doi:10.1016/j.neulet.2012.10.021 PubMedCrossRef

24.

Zhang X, Zhu W, Zhang J, Huo S, Zhou L, Gu Z, Zhang M (2010) MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun 395(2):275–280. doi:10.1016/j.bbrc.2010.04.005 PubMedCrossRef

25.

Feng L, Xie Y, Zhang H, Wu Y (2011) Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun 406(4):534–538. doi:10.1016/j.bbrc.2011.02.081 PubMedCrossRef

26.

Zeng ZL, Li FJ, Gao F, Sun DS, Yao L (2013) Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol 107(2):105–110. doi:10.1002/jso.23210 PubMedCrossRef

27.

Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, Verner J, Doubek M, Brychtova Y, Trbusek M, Hampl A, Mayer J, Pospisilova S (2012) MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood 119(9):2110–2113. doi:10.1182/blood-2011-11-394874 PubMedCrossRef

28.

Li W, Chu D, Chu X, Meng F, Wei D, Li H, Sun B (2011) Decreased expression of NDRG2 is related to poor overall survival in patients with glioma. J Clin Neurosci 18(11):1534–1537. doi:10.1016/j.jocn.2010.12.032 PubMedCrossRef

29.

Sun B, Chu D, Li W, Chu X, Li Y, Wei D, Li H (2009) Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neuro Oncol 94(2):213–219. doi:10.1007/s11060-009-9859-7 CrossRef

30.

Wang F, Sun GP, Zou YF, Hao JQ, Zhong F, Ren WJ (2012) MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark 11(6):259–267. doi:10.3233/CBM-2012-00284 PubMed

31.

Tang W, Zhu J, Su S, Wu W, Liu Q, Su F, Yu F (2012) MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One 7(12):e51702. doi:10.1371/journal.pone.0051702 PubMedCrossRef

32.

Melotte V, Qu X, Ongenaert M, van Criekinge W, de Bruine AP, Baldwin HS, van Engeland M (2010) The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 24(11):4153–4166. doi:10.1096/fj.09-151464 PubMedCrossRef

Titel: MicroRNA-650 expression in glioma is associated with prognosis of patients
verfasst von: Boqian Sun
Bo Pu
Dake Chu
Xiaodan Chu
Wei Li
Dun Wei
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1243-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression

Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis

Prognostic value of Musashi-1 in gliomas

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa